

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

INSIDE INFORMATION: 2021 PRELIMINARY RESULTS ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This preliminary results announcement has been prepared in accordance with the relevant regulations of the Shanghai Stock Exchange and the PRC. The key financial data of the Company for 2021 as set out in this announcement is preliminarily calculated in accordance with the PRC Accounting Standards and has not been audited by an accounting firm. The audited financial data of the Company for 2021 will be disclosed in the 2021 annual report of the Company (prepared in accordance with PRC GAAP) to be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the 2021 annual results announcement and the 2021 annual report (prepared in accordance with the International Financial Reporting Standards) to be published on the website of the Company (<https://www.joinnlabs.com>) and the website of the Stock Exchange (<http://www.hkexnews.hk>). Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This preliminary results announcement has been prepared in accordance with the relevant regulations of the Shanghai Stock Exchange and the PRC. The key financial data of JOINN Laboratories (China) Co., Ltd. (the “Company”) for 2021 as set out in this announcement is preliminarily calculated in accordance with the PRC Accounting Standards and has not been audited by an accounting firm. The audited financial data of the Company for 2021 will be disclosed in the 2021 annual report of the Company (prepared in accordance with PRC GAAP) to be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the 2021 annual results announcement and the 2021 annual report (prepared in accordance with the International Financial Reporting Standards) to be published on the website of the Company (<https://www.joinnlabs.com>) and the website of the Stock Exchange (<http://www.hkexnews.hk>).

Set out below is the announcement published by the Company on the website of the Shanghai Stock Exchange for reference only. Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson

Beijing, the PRC, 24 February 2022

As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, Mr. Gu Xiaolei as a non-executive Director, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.

E DD BW W W "B
c F bc W H b ((



The main financial data for 2021 set out in this announcement is preliminary accounting data, which has not been audited by an accounting firm. The specific data shall be subject to the data disclosed in the 2021 annual report of the Company. Investors are advised to pay attention to investment risks.

I . Key Financial Data and Indicators for 2021

Unit: RMB million

c	H F	BW W	W
	H F	H F	W

Note: 1. The opening balance of this report is the amount of last year legally disclosed.
2. In 2021, the Company implemented the conversion of capital reserve into share capital, and the earnings per share for the corresponding period of last year has been recalculated according to the changed share capital.

II . Operating Results and Financial Position

1. Impact of principal business

2. Effect of non-operating profit or loss

) **I W B**

III. Risk Warning

The main financial data for 2021 contained in this announcement is preliminary accounting data, which has not been audited by an accounting firm. The specific data shall be subject to the data disclosed in the 2021 annual report of the Company. Investors are advised to pay attention to investment risks.

IV. Filing Attachment

The comparative balance sheet and income statement signed and sealed by the current legal representative of the Company, the person-in-charge of accounting affairs and the person-in-charge of the accounting department (head of the accounting department).

This announcement is hereby made.

The Board of Directors
JOINN Laboratories (China) Co., Ltd.
24 February 2022